Q1 EPS Estimate for Eton Pharmaceuticals Raised by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at B. Riley increased their Q1 2025 earnings estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings per share of $0.06 for the quarter, up from their previous forecast of $0.03. B. Riley currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.00 EPS.

A number of other research analysts have also weighed in on ETON. Craig Hallum lifted their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a research note on Wednesday.

Eton Pharmaceuticals Trading Down 3.8 %

Eton Pharmaceuticals stock opened at $14.22 on Thursday. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41. The firm has a market capitalization of $370.45 million, a price-to-earnings ratio of -64.64 and a beta of 1.37. The firm has a 50 day simple moving average of $15.58 and a 200 day simple moving average of $11.54.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The business had revenue of $11.65 million during the quarter, compared to analyst estimates of $10.53 million.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ETON. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Eton Pharmaceuticals by 86.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after purchasing an additional 30,167 shares in the last quarter. Wasatch Advisors LP bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth $1,431,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth $54,000. Parkman Healthcare Partners LLC lifted its holdings in shares of Eton Pharmaceuticals by 2.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock worth $1,561,000 after acquiring an additional 7,029 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Eton Pharmaceuticals during the 3rd quarter worth $90,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.